Not surprisingly, both animal studies and clinical experiences demonstrate that blockage of VEGF signaling is a valid approach for the treatment of AMD although the therapeutic efficacy for diabetic retinopathy and ROP needs further validation in appropriate animal models. This evidence concerns the gene VEGFA and retinopathy of prematurity.